Understanding heart failure with preserved ejection fraction: where are we today?

[1]  Thomas Danner,et al.  Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease , 2015, Nature.

[2]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[3]  Michael A. Burke,et al.  Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[4]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[5]  Grace Lin,et al.  Right heart dysfunction in heart failure with preserved ejection fraction. , 2014, European heart journal.

[6]  Giuseppe Ambrosio,et al.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.

[7]  M. Runge,et al.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. , 2014, International journal of cardiology.

[8]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[9]  Wolfgang A. Linke,et al.  Gigantic Business: Titin Properties and Function Through Thick and Thin , 2014, Circulation research.

[10]  Michael A. Burke,et al.  Prognostic Importance of Pathophysiologic Markers in Patients With Heart Failure and Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[11]  E. Braunwald,et al.  Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study , 2014, Circulation. Heart failure.

[12]  W. Paulus,et al.  Biomarkers of heart failure with normal ejection fraction: a systematic review , 2013, European journal of heart failure.

[13]  M. Black,et al.  Obesity Is Associated with Lower Coronary Microvascular Density , 2013, PloS one.

[14]  G. Maurer,et al.  Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction , 2013, Circulation. Cardiovascular imaging.

[15]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[16]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[17]  S. Umemura,et al.  Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. , 2012, Journal of the American College of Cardiology.

[18]  Arshed A Quyyumi,et al.  Endothelial dysfunction, arterial stiffness, and heart failure. , 2012, Journal of the American College of Cardiology.

[19]  J. Bronzwaer,et al.  Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.

[20]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[21]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[22]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[23]  C. Tschöpe,et al.  Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. , 2011, Journal of the American College of Cardiology.

[24]  P. Steendijk,et al.  Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.

[25]  Amir Lerman,et al.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.

[26]  M. Goligorsky,et al.  Microvascular rarefaction , 2010, Organogenesis.

[27]  A. Henning,et al.  Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. , 2009, Journal of the American College of Cardiology.

[28]  V. Roger,et al.  Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. , 2009, Journal of the American College of Cardiology.

[29]  M. Keane,et al.  Time-Varying Myocardial Stress and Systolic Pressure-Stress Relationship: Role in Myocardial-Arterial Coupling in Hypertension , 2009, Circulation.

[30]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[31]  J. Bronzwaer,et al.  Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium , 2009, Circulation research.

[32]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[33]  Sandeep N. Gupta,et al.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. , 2008, Journal of the American College of Cardiology.

[34]  F. Sellke,et al.  The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. , 2008, Current vascular pharmacology.

[35]  J. Bronzwaer,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.

[36]  Wolfgang Hoffmann,et al.  Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction , 2008, Circulation.

[37]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[38]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[39]  D. Kass,et al.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.

[40]  D. Kass,et al.  Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction , 2006, Circulation.

[41]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[42]  Wolfgang A Linke,et al.  Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure , 2006, Circulation.

[43]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[44]  Istvan Edes,et al.  Cardiomyocyte Stiffness in Diastolic Heart Failure , 2005, Circulation.

[45]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[46]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[47]  D. Kass,et al.  Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations , 2003, Circulation.

[48]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[49]  E. Takimoto.  Cyclic GMP-dependent signaling in cardiac myocytes. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[50]  C. Spradley.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2012 .

[51]  D. Kass,et al.  Ventricular-vascular interaction in heart failure. , 2008, Heart failure clinics.